 participate in CREST based on low volume or high complication rate.205 It is unclear if similar
results will be obtained for CAS among clinicians who
are less experienced or among patients who would not
meet inclusion criteria for the clinical trial. Nolan
et al206 reviewed data from the Northern New England
Vascular Registry and showed a higher risk of stroke
and death in symptomatic patients treated with CAS
compared with CEA (5.1% CAS vs 1